Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Executive Summary
Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.
You may also be interested in...
Pfizer Hits Pause On M&A To See How US Tax Reform Plays
CEO Ian Read indicated the company will wait to see if the US tax system is overhauled before completing any large-scale M&A, even as many investors are anxious to see Pfizer make an acquisition.
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
Bristol's New Chief Scientific Officer Lists Oncology Priorities, But Little New
At ASCO, Bristol-Myers-Squibb's new Chief Scientific Officer Thomas Lynch highlighted key R&D priorities for advancing the company's cancer pipeline and staying ahead of its competitors.